低剂量阿帕替尼联合tiggio治疗铂基方案失败后复发或转移性头颈部鳞状癌的临床观察

Q4 Medicine

肿瘤研究与临床 Pub Date : 2020-03-28 DOI:10.3760/CMA.J.CN115355-20190620-00259

Yan Wu, Ying-can Lu, M. Tao

{"title":"低剂量阿帕替尼联合tiggio治疗铂基方案失败后复发或转移性头颈部鳞状癌的临床观察","authors":"Yan Wu, Ying-can Lu, M. Tao","doi":"10.3760/CMA.J.CN115355-20190620-00259","DOIUrl":null,"url":null,"abstract":"目的 \n观察低剂量阿帕替尼联合替吉奥治疗铂类方案失败复发或转移性头颈部鳞状细胞癌（HNSCC）的近期疗效及患者不良反应。 \n \n \n方法 \n回顾性分析江苏省连云港市第二人民医院2017年3月至2019年2月收治的26例铂类方案失败复发或转移性HNSCC患者，口服阿帕替尼250 mg/d，替吉奥每天60 mg/m2，分早晚2次口服，第1天至第14天，休息7 d，每21 d为1个周期，完成2个周期进行疗效评价，并观察患者不良反应。 \n \n \n结果 \n26例患者中，无完全缓解，部分缓解4例，疾病稳定16例，疾病进展6例。客观缓解率为15.3%（4/26），疾病控制率为76.9%（20/26），中位无进展生存期为3.8个月（2.1~6.3个月），患者不良反应主要是高血压、血小板下降、乏力等。 \n \n \n结论 \n低剂量阿帕替尼联合替吉奥治疗铂类方案失败复发或转移性HNSCC近期疗效较好，患者不良反应可耐受，有潜在临床推广应用价值。","PeriodicalId":9505,"journal":{"name":"肿瘤研究与临床","volume":"32 1","pages":"197-199"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical observation of low dose apatinib combined with tiggio in the treatment of recurrent or metastatic head and neck squamous carcinoma after failure of platinum-based regimen\",\"authors\":\"Yan Wu, Ying-can Lu, M. Tao\",\"doi\":\"10.3760/CMA.J.CN115355-20190620-00259\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"目的 \\n观察低剂量阿帕替尼联合替吉奥治疗铂类方案失败复发或转移性头颈部鳞状细胞癌（HNSCC）的近期疗效及患者不良反应。 \\n \\n \\n方法 \\n回顾性分析江苏省连云港市第二人民医院2017年3月至2019年2月收治的26例铂类方案失败复发或转移性HNSCC患者，口服阿帕替尼250 mg/d，替吉奥每天60 mg/m2，分早晚2次口服，第1天至第14天，休息7 d，每21 d为1个周期，完成2个周期进行疗效评价，并观察患者不良反应。 \\n \\n \\n结果 \\n26例患者中，无完全缓解，部分缓解4例，疾病稳定16例，疾病进展6例。客观缓解率为15.3%（4/26），疾病控制率为76.9%（20/26），中位无进展生存期为3.8个月（2.1~6.3个月），患者不良反应主要是高血压、血小板下降、乏力等。 \\n \\n \\n结论 \\n低剂量阿帕替尼联合替吉奥治疗铂类方案失败复发或转移性HNSCC近期疗效较好，患者不良反应可耐受，有潜在临床推广应用价值。\",\"PeriodicalId\":9505,\"journal\":{\"name\":\"肿瘤研究与临床\",\"volume\":\"32 1\",\"pages\":\"197-199\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-03-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"肿瘤研究与临床\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.CN115355-20190620-00259\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"肿瘤研究与临床","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.CN115355-20190620-00259","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

Objective: To observe the short-term efficacy and adverse reactions of low-dose apatinib combined with tigio in the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) after failure of platinum based regimens. Method: A retrospective analysis was conducted on 26 patients with recurrent or metastatic HNSCC who were admitted to the Second People's Hospital of Lianyungang City, Jiangsu Province from March 2017 to February 2019 due to failure of the platinum regimen. They received 250 mg/d of apatinib orally and 60 mg/m2 of tiggio daily, twice a day in the morning and evening. From day 1 to day 14, they rested for 7 days, and every 21 days was a cycle. Two cycles were completed for efficacy evaluation and adverse reactions were observed. Among the 26 patients, there were no complete remission, 4 partial remission, 16 stable disease, and 6 disease progression. The objective response rate was 15.3% (4/26), the disease control rate was 76.9% (20/26), and the median progression free survival period was 3.8 months (2.1-6.3 months). The main adverse reactions of patients were hypertension, thrombocytopenia, and fatigue. Conclusion: Low dose Apatinib combined with Tegio has a good short-term efficacy in the treatment of recurrent or metastatic HNSCC caused by platinum based regimens, and the patient's adverse reactions are tolerable, which has potential clinical promotion and application value.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Clinical observation of low dose apatinib combined with tiggio in the treatment of recurrent or metastatic head and neck squamous carcinoma after failure of platinum-based regimen

目的观察低剂量阿帕替尼联合替吉奥治疗铂类方案失败复发或转移性头颈部鳞状细胞癌（HNSCC）的近期疗效及患者不良反应。方法回顾性分析江苏省连云港市第二人民医院2017年3月至2019年2月收治的26例铂类方案失败复发或转移性HNSCC患者，口服阿帕替尼250 mg/d，替吉奥每天60 mg/m2，分早晚2次口服，第1天至第14天，休息7 d，每21 d为1个周期，完成2个周期进行疗效评价，并观察患者不良反应。结果 26例患者中，无完全缓解，部分缓解4例，疾病稳定16例，疾病进展6例。客观缓解率为15.3%（4/26），疾病控制率为76.9%（20/26），中位无进展生存期为3.8个月（2.1~6.3个月），患者不良反应主要是高血压、血小板下降、乏力等。结论低剂量阿帕替尼联合替吉奥治疗铂类方案失败复发或转移性HNSCC近期疗效较好，患者不良反应可耐受，有潜在临床推广应用价值。

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

肿瘤研究与临床 Medicine-Oncology

CiteScore

0.10

自引率

0.00%

发文量

7737

期刊介绍： "Cancer Research and Clinic" is a series of magazines of the Chinese Medical Association under the supervision of the National Health Commission and sponsored by the Chinese Medical Association. It mainly reflects scientific research results and academic trends in the field of malignant tumors. The main columns include monographs, guidelines and consensus, standards and norms, treatises, short treatises, survey reports, reviews, clinical pathology (case) discussions, case reports, etc. The readers are middle- and senior-level medical staff engaged in basic research and clinical work on malignant tumors.